New biologic mirikizumab put to the test against standard therapies for IBD
Disease control
Not yet recruiting
This study compares the real-world effectiveness of mirikizumab against standard biologic therapies for adults with ulcerative colitis or Crohn's disease. Researchers will track whether mirikizumab reduces the need for extra medical care, like emergency visits or treatment change…
Phase: PHASE4 • Sponsor: Specialty Networks Research. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC